You are here

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics

Dohee Kwon, Jaemoon Koh, Sehui Kim, et al.

Lung Cancer, Volume 106, April 2017, Pages 131–137

Commentary by Stefan Zimmermann

Our understanding of MET as an actionable target, more specifically MET exon 14 skipping alterations, found in 3% of both non-squamous and squamous advanced NSCLC, has allowed the use of crizotinib and the development of newer MET inhibitors. Yet much remains unknown regarding the clinicopathological characteristics of these tumors. In this series of 147 triple negative (EGFR-, ALK-, and KRAS-) carcinomas, 8.8% of adenocarcinomas and 20% of pleomorphic carcinomas harbored were METex14+. In contrast to EGFR mutations, the MET mutation rate was independent of ethnicity, the alteration was observed in older individuals (median age 73), and there was no statistical association with smoking status. This is an important reminder to screen patients, including older individual with acinar adenocarcinoma and pleomorphic carcinoma. Indeed, after the failure of several high-profile trials, the development of MET TKIs is regaining momentum with tepotinib (NCT02864992), savolitinib (NCT02897479), capmatinib (NCT02750215), glesatinib (NCT02544633) and merestinib (NCT02920996)!

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

A few pearls from ELCC 2017

5-8 May 2017, Geneva

by Stefan Zimmermann

A high-level forum where critical issues we face as thoracic oncologists are discussed, and cutting-edge new research is presented. 

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease

Now available: Webcast on demand


Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.